Stockreport

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Phathom Pharmaceuticals, Inc.  (PHAT) 
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am Check Earnings Report
PDF Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for T [Read more]